Zenas BioPharma (ZBIO) Net Cash Flow (2023 - 2026)

Zenas BioPharma's Net Cash Flow history runs 4 years deep, the most recent figure standing at $389.9 million for Q1 2026.

• On a quarterly basis, Net Cash Flow rose 416.41% year-over-year to $389.9 million in Q1 2026; TTM through Mar 2026 was $304.2 million, a 91.02% increase from a year earlier, with the FY2025 full-year figure at -$208.9 million, down 179.53% from the prior year.
• Net Cash Flow improved to $389.9 million in Q1 2026 per ZBIO's latest filing, from -$4.9 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $389.9 million in Q1 2026 and bottomed at -$152.3 million in Q2 2025.
• The 4-year median for Net Cash Flow is -$10.1 million (2023), against an average of $42.8 million.
• Across the five-year window, Net Cash Flow plunged 524.31% in 2025 and jumped 416.41% in 2026, its largest moves.
• Year by year, Net Cash Flow stood at -$15.4 million in 2023, then slumped by 163.43% to -$40.4 million in 2024, then surged by 87.8% to -$4.9 million in 2025, then jumped by 8000.59% to $389.9 million in 2026.
• Per Business Quant, the three latest ZBIO Net Cash Flow figures stand at $389.9 million (Q1 2026), -$4.9 million (Q4 2025), and $71.5 million (Q3 2025).